Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Dupont Circle Physician's Group, Washington D.C.

Capital Medical Associates, PC, Washington D.C.

Orlando Immunology Center, Orlando

Gordon E. Crofoot, MD, PA, Houston

Central Texas Clinical Research, Austin

Kaiser Permanente Los Angeles, Los Angeles

Peter J. Ruane, MD, Inc., Los Angeles

Anthony Mills MD, Inc, Los Angeles

Community Research Initiative of New England, Boston